Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Emtricitabine/tenofovir alafenamide - Gilead Sciences

Next Previous
Drug Profile

Emtricitabine/tenofovir alafenamide - Gilead Sciences

Alternative Names: DESCOVY; F/TAF; Tenofovir alafenamide/emtricitabine

Latest Information Update: 16 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences
  • Developer Clinton Health Access Initiative; Gilead Sciences; Japan Tobacco; National Institute of Allergy and Infectious Diseases; PENTA Foundation
  • Class Antiretrovirals; Deoxyribonucleosides; Purines; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 09 Mar 2025 Adverse events data from a phase II/III trial in HIV-1 infections presented at the 32nd Conference on Retroviruses and Opportunistic Infections 2025 (CROI-2025)
  • 11 Dec 2024 Gilead completes phase-II/III clinical trials in HIV-1 infections (Adjunctive treatment, In children, In adolescents, In infants) in US, South Africa and Panama (PO) (NCT02285114)
  • 19 Dec 2023 University of Washington and Gilead Sciences completes a Phase-II/III clinical trials in HIV-1 infections (Prevention) in Kenya (PO) (NCT05140954)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top